{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:02:25Z","timestamp":1792245745898,"version":"4.4.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd"},{"name":"Basilea Pharmaceutica International Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/jac\/dky463","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T19:14:25Z","timestamp":1539717265000},"page":"761-767","source":"Crossref","is-referenced-by-count":76,"title":["Variability and exposure\u2013response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases"],"prefix":"10.1093","volume":"74","author":[{"given":"Thomas","family":"Kaindl","sequence":"first","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Saulay","sequence":"additional","affiliation":[{"name":"ICON plc, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Larger","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology, University Children\u2019s Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"key":"key\n\t\t\t\t2019021507303356700_dky463-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/2040620716656381","article-title":"Recent developments in the management of invasive fungal infections in patients with oncohematological diseases","volume":"7","author":"Ruhnke","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2016","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B6","author":"Lewis"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","article-title":"Treatment of invasive fungal infections in cancer patients\u2014updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"93","author":"Mousset","year":"2014","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","article-title":"Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Hamada","year":"2013","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B9","doi-asserted-by":"crossref","first-page":": e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B15","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B16","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure\u2013response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B19","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B20","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B21","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B22"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B24","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/AAC.01316-08","article-title":"Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Trifilio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B25","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","article-title":"Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole","volume":"55","author":"Hohmann","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B28","doi-asserted-by":"crossref","first-page":"a019653.","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B29","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303356700_dky463-B30","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/3\/761\/27785412\/dky463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T12:47:08Z","timestamp":1550234828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/3\/761\/5195622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,21]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,21]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky463","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,11,21]]}}}